1-(2-Methylpropyl)-4-nitrosobenzene | 293751-45-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-Methylpropyl)-4-nitrosobenzene
• CAS: 293751-45-8
• 化学式: C₁₀H₁₃NO
• 分子量: 163.22
• InChiKey: MCAMQUFQEWSGIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Continuous process for the conversion of olefins and carbon dioxide to acrylates via solution phase reactor
  申请人：CHEVRON PHILLIPS CHEMICAL COMPANY LP

  公开号：US10544080B2

  公开（公告）日：2020-01-28

  Disclosed is a continuous process for producing α,β-unsaturated carboxylic acids or salts thereof, comprising: 1) in a first stage, contacting (a) a transition metal precursor compound comprising at least one first ligand, (b) optionally, at least one second ligand, (c) an olefin, (d) carbon dioxide (CO2), and (e) a diluent to form a first composition; 2) in a second stage, contacting a polyanionic solid with the first composition to form a second composition; and 3) in a third stage, (a) contacting the second composition with a polar solvent to release a metal salt of an α,β-unsaturated carboxylic acid and form a reacted solid. Methods of regenerating the polyanionic solid are described.

  本发明公开了一种生产α，β-不饱和羧酸或其盐的连续工艺，包括1) 在第一阶段，将(a)包含至少一种第一配体的过渡金属前体化合物、(b)可选的至少一种第二配体、(c)烯烃、(d)二氧化碳（CO2）和(e)稀释剂接触，形成第一组合物；2) 在第二阶段，将聚阴离子固体与第一种组合物接触，形成第二种组合物；以及 3) 在第三阶段，(a) 将第二种组合物与极性溶剂接触，释放出 α，β-不饱和羧酸的金属盐，形成反应固体。描述了再生聚阴离子固体的方法。
• Somatostatin receptor antagonist compounds and methods of using the same
  申请人：CDRD VENTURES INC.

  公开号：US11279732B2

  公开（公告）日：2022-03-22

  The present invention is directed to somatostatin receptor antagonist compounds having the structure of Formula I, compositions comprising the same, and methods of using such compounds and compositions. The compounds may be useful in the prevention or treatment of hypoglycemia.

  本发明涉及具有式 I 结构的体生长抑素受体拮抗剂化合物、包含这些化合物的组合物以及使用这些化合物和组合物的方法。这些化合物可用于预防或治疗低血糖症。
• SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME
  申请人：CDRD VENTURES INC.

  公开号：US20190040102A1

  公开（公告）日：2019-02-07

  The present invention is directed to somatostatin receptor antagonist compounds having the structure of Formula I, compositions comprising the same, and methods of using such compounds and compositions. The compounds may be useful in the prevention or treatment of hypoglycemia.
• [EN] HETEROCYCLIC COMPOUNDS AS DCTPP1 MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DCTPP1
  申请人：THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING

  公开号：WO2016055582A1

  公开（公告）日：2016-04-14

  The invention relates to compoundsof formula I, or a pharmaceutically-acceptable salt thereof. The present invention also relates to pharmaceutical formulations comprising these compounds, and to their use as medicaments for the treatment of disorders where modulation of DCTPP (deoxycytidine triphosphate pyrophosphatase 1) activity exerts a therapeutic effect.